This is a clinical trial for: Autoimmune Hepatitis (AIH)

In Autoimmune Hepatitis (AIH), the body’s immune system attacks the cells of the liver, causing the liver to become inflamed. The goal of AIH treatment is to suppress liver inflammation and prevent progression to cirrhosis and liver failure, but the existing standard of care isn’t fully effective for all AIH patients. This clinical trial will research the safety and effectiveness of an investigational medication for AIH patients who are intolerant of or haven’t responded completely to existing treatments.

Check eligibility

Study details

Eligibility requirements

Participants must:

  • Be between 18 and 75 years old
  • Have been diagnosed with Autoimmune Hepatitis (AIH)

Participants must not:

  • Have Hepatitis B or C
  • Have NASH, PBC, PSC, decompensated cirrhosis, or HIV

If you would like to speak to someone regarding this trial, first check to see if you are eligible above. If it seems that you are eligible to take part, you will be contacted by phone, and you will be able to ask any additional questions you may have about this clinical trial.